Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.